Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

ITI-333 shows promise for the treatment of pain and substance abuse-derived disorders

Dec. 24, 2018

Adial engages CRO to oversee phase III trial of AD-04 for alcohol use disorder

Nov. 23, 2018

Weekly and monthly Buvidal approved in Europe for opioid dependence

Nov. 23, 2018

Blocking BigLEN-GRP171 signaling reduces opioid addiction and withdrawal in mice

Nov. 15, 2018

KemPharm adds drug for stimulant use disorder to pipeline

Nov. 15, 2018

TMPRSS11E gene identified as a novel biomarker of smoking-related traits in Europeans

Oct. 30, 2018

France becomes first country to market baclofen preparation to reduce alcohol consumption

Oct. 29, 2018

Enzyme instead of antibody to kick smoking habit?

Oct. 23, 2018

NIH grant to support advancement of heroin vaccine OPNT-005

Oct. 22, 2018

Eagle enters agreement with USAMRICD to evaluate neuroprotective effects of Ryanodex

Oct. 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...